VitaScreen — CMA Screening What you don't measure, you can't optimize.

Mitochondrial & Longevity Diagnostics in 5 Minutes.

Right in your practice. At the Point‑of‑Care.

VitaScreen objectively measures cellular oxidative stress — from a single drop of blood, in 5 minutes. One number that shows you whether your therapy is working: before treatment, after, and over time.

Book a 30‑min consultation → Request studies & info material

Sample

1 drop of blood

Time to result

5 minutes

Method

CMA · EPR‑based

The problem

Until now, oxidative stress could only be estimated — not steered.

Conventional markers like MDA, 8‑OHdG or TAS measure the end products of radical reactions — hours to days after the reaction has taken place. What's happening in the cell right now stays invisible.

−
External lab, days of wait time. Therapy adjustment only happens at the next appointment.
−
Indirect markers. Estimation instead of quantification of actual ROS activity.
−
Before/after impossible. Treatment outcome stays subjective — recommendation instead of evidence.
−
No practice ROI. Hard to position as a private/IGeL service without a visible result.

The consequence

Therapies that get recommended without objective proof of effect.

Patients feel an effect — or they don't. Practices can't show that an intervention is working, and can't steer when to adjust it.

~7 days

Typical turnaround MDA / 8‑OHdG

5 min

VitaScreen at the Point‑of‑Care

VitaScreen vs. conventional diagnostics

Measure directly — don't calculate around it.

VitaScreen quantifies ROS directly via the patented CMA method (Cellular Metabolic Activity, EPR/ESR‑based) — at the patient's side, with no lab shipment.

Criterion

MDA / 8‑OHdG

TAS / TBARS

VitaScreen · CMA

Measuring principle

− End product, indirect

− Global status

✓ Direct: ROS activity

Time to result

3–7 days

2–5 days

✓ < 5 minutes

Sample

Venous blood draw

✓ 1 capillary drop

Before/after

− Weeks delayed

− Limited

✓ In the same session

Place of measurement

External lab

✓ Practice · Point‑of‑Care

Therapy steering

Retrospective

✓ Iterative, evidence-based

← scroll table sideways →

Methodological foundation: EPR spectroscopy (electron paramagnetic resonance) — the recognised gold standard for direct radical detection.¹

How it works

Four steps — from drop to therapy decision.

Capillary sample — drop of blood from the fingertip — 01 · Sample One capillary drop from the fingertip. Venous draw also possible.

Capillary being inserted into the VitaScreen sample chamber — 02 · Measurement Measurement on-site after sample preparation. No lab shipment.

Take the drop

A capillary sample from the fingertip — like a blood-glucose test. Venous draw also possible.

~ 30 sec.

CMA measurement

The device quantifies cellular ROS activity in real time — directly, not via end products.

~ 5 min.

Interpret values

Marker profile with reference range and comparison to baseline. Clearly readable for clinician and patient.

Immediate

Steer the therapy

Adjust the intervention, re-measure after weeks — document the outcome objectively.

Repeatable

CMA247 nM/s eCMA MITO eCMA iNOS Sample marker profile · values are fictional

Method & evidence

EPR precision. On the practice desk.

The patented CMA method (Cellular Metabolic Activity) is a cellular test based on EPR spectroscopy, run on the miniaturised EPR spectrometer VitaScreen. It measures ROS formation in blood cells under physiological conditions (T = 36.6 °C, pO₂ 40 mmHg) — as simple as a blood-glucose test, no cryogenics, no specialist lab.

1 drop

Capillary blood from the fingertip

36.6 °C

Physiological measurement (pO₂ 40 mmHg)

> 25

Correlated lab & functional parameters²

IVDR‑IVD

Status labelled per application

R&D applications (longevity markers) are clearly flagged in the marker profile.

VitaScreen in a clinical setting — capillary sample

EPR · ROS spectrum Sample

ROS formation in nM/s Values are fictional

CMA reference scale from 220 to 300 nM/s: 220–240 oxidative eustress (normal, green), 250–270 risk (yellow-orange), 280–300 high risk (red). — 220–240 nM/s marks oxidative eustress — the healthy corridor. From 250 nM/s oxidative distress begins; above 280 the high-risk range.² Orientation values from normalised control cohorts across several publications — they don't replace a medical diagnosis.

Cellular Metabolic Activity Pattern — bar chart of ROS formation in nM/s for Healthy, COVID19, Cardiotoxicity and CAD/Met. Syndrome, broken down by eCMA markers. — VitaScreen first delivers a total value — and on demand the underlying profile: MITO, ENDO, iNOS, PHAGO NOX and INFLA. This makes different pathophysiological patterns visible.³

The evidence

When the CMA value drops, the whole system improves.

A favourable reduction in the CMA value correlates with measurable improvements across more than 25 laboratory, metabolic, inflammatory and functional cardiac parameters.²

Excerpt from the "Human Oxidative Stress & Performance Evaluation" study (HOPE)

CMA▼ 19.7 %

NO•▲ 190 %

Systolic blood pressure

▼ 7.1 %

HDL cholesterol

▲ 10.9 %

hsCRP

▼ 25.1 %

Heart rate (100 W)

▼ 10.6 %

LDL cholesterol

▼ 7.6 %

TNF‑α resistance

▲ 53.8 %

Shown are representative changes in cardiac function, lipid metabolism and inflammatory markers in relation to CMA and endothelial function (NO levels), after 3 months on a multifunctional supplement containing 22 essential trace minerals, oligo-vitamins, omega-3 fatty acids EPA and DHA, grape seed and grape skin extracts, extracts of devil's claw, turmeric and ginger, plus probiotic bacteria.⁷

Use cases

Therapy steering for practices that demand evidence of effect.

For doctors, therapists and practitioners who want to document treatment outcomes objectively — and show their patients measurable progress over time.

IHHT & altitude training

Steer hypoxia sessions adaptively: measure baseline, dose the training stimulus, document recovery. Stress load as an objective control variable instead of SpO₂ guesswork.

CMAeCMA MITOBefore/after

R&D⁴

Longevity & prevention

Marker profile for patients with a longevity focus — as part of a structured programme. Repeated measurements over months.

SIRT1AMPKIGF1mTOR

Generalised endotheliitis

eCMA iNOS for objective follow-up in patients with Long-COVID / ME-CFS symptoms.

eCMA iNOSFollow-up monitoring

The origin story

From the research lab to the practice — the journey behind VitaScreen.

Together with Noxygen, Dr. med. Bruno Fink spent years researching the direct measurement of oxidative species — what used to require a specialist lab and cryogenics is now delivered on the practice desk as the patented CMA method.

01 The spark

What are you actually measuring?

The fundamental research question: what are you measuring when you measure oxidative stress — and why do end-product markers only show what happened days later? EPR/ESR detects reactive species directly — but until now only in specialist labs.

Research question

02 The breakthrough

EPR straight from the drop.

Out of the ESR methodology of basic research grew the patented CMA — a compacted variant that quantifies paramagnetic species from cellular metabolism without cryogenics. Hours turn into minutes.

Method transfer

03 The handback

Practice-ready. For every desk.

What used to need specialist know-how in the lab now runs at the Point‑of‑Care: 1 capillary drop, a marker profile in under 5 minutes, with clearly readable reference ranges. Therapy becomes steerable.

Point‑of‑Care

In post-COVID we see a clear pattern at the cellular level: four enzymes are overexpressed — inducible NO synthase, NOX1, the mitochondria and the phagocytic NADPH oxidase. The strongest contribution comes from iNOS. Exactly this pattern becomes visible — where the standard lab stays silent.

Dr. med. Bruno Fink · Founder & CEO Noxygen · developer of the CMA method

Voices from practice

What practices change with VitaScreen.

The developers and experts behind VitaScreen — plus a documented case from a NOXYGEN study. Individual cases; no generalised or guaranteed outcome.

5 min

Result in the same appointment

1 drop

Capillary blood from the fingertip

> 25

Correlated parameters²

Private

Billable as a private service⁵

"We finally have a point where we can really see what happens right after — and how long it takes for the cells to recover."

Jürgen ReinmuthIHHT expert & protocol developer · works with more than 900 practices

"I always thought I was healthy …"
Mark, 47, a passionate athlete — and yet exhausted every day. His CMA value revealed a cardiovascular risk that nothing on the surface suggested. After an adjusted training programme, his values were back in the healthy range a year later.

Individual results vary. Case description from a NOXYGEN study; no curative or outcome promise.⁶

VitaScreen is an IVDR-compliant in-vitro diagnostic (IVD). EPR (electron paramagnetic resonance) is regarded as the gold standard for direct radical detection (Sies et al., Annual Review of Biochemistry 2017).

CMA scale (220–300 nM/s): orientation values from the Noxygen reference database; does not replace a medical diagnosis. "> 25 correlations" refers to the overall CMA method corpus (manufacturer statement), not to the individual measurement.

eCMA differential analysis (MITO/ENDO/iNOS/PHAGO NOX2/INFLA) evaluated in human studies (incl. Fink et al., Int. J. Mol. Sci. 2025 — industry-funded pilot study, proof-of-concept; independent replication pending).

Longevity markers (SIRT1, AMPK, IGF-1, mTOR) are intended exclusively for research and development (R&D) — not a billable routine service.

IHHT data: Balestra et al., Int. J. Mol. Sci. 2021, 22:9600 (proof-of-principle, n=26, young healthy subjects). Private billing possible; reimbursement is not guaranteed and must be clarified case by case with the payer.

Case "Mark": progress description from a NOXYGEN study (manufacturer statement). Individual results vary — no curative or outcome promise.

"Human Oxidative Stress & Performance Evaluation" study (HOPE): the values shown are representative changes in relation to CMA after 3 months on a supplement (manufacturer statement). They document the correlation of the CMA value, not an effect of VitaScreen. No curative or outcome promise.